TY - JOUR
T1 - PRECLINICAL RESEARCH AND SYSTEMATIC PRODUCTION OF INNOVATIVE MEDICAL RADIO-ISOTOPES AT ISOL@MYRRHA
AU - Popescu, Lucia
AU - Pauwels, Dieter
AU - Aerts, An
AU - Aït Abderrahim, Hamid
AU - Baatout, Sarah
AU - Baeten, Peter
AU - Gijs, Marlies
AU - Huyse, M.
AU - Impens, Nathalie
AU - Neyens, G.
AU - Raabe, R.
AU - Severijns, N.
AU - Schuurmans, Paul
AU - Schyns, Marc
AU - Temst, K.
AU - Van Duppen, P.
AU - Vantomme, A.
AU - Wagemans, Jan
N1 - Score = 10
PY - 2012/3
Y1 - 2012/3
N2 - The wide spectrum of radioactive ion beams that can be produced and the fact that they can be obtained essentially carrier free, makes ISOL facilities a unique tool for preclinical studies of innovative radioisotopes. Such kind of studies is being carried out already at existing facilities, like at CERN-ISOLDE. An illustrative example is the production of 149Tb, for which promising results were observed in a dedicated alpha-therapy study on Severe Combined Immuno-Deficient (SCID) mice. However, the demand for beam time at ISOL facilities is extra-ordinary, resulting in typical beam-time periods for an experiment of several days up to two weeks at maximum. ISOL@MYRRHA, on the other hand, will be unique in the sense that programs in need of extended beam times will be prioritized. In combination with the intense RIBs, this might open the possibility to produce in a systematic manner innovative carrier-free radioisotopes like, for example, the alpha-emitter 149Tb and the PET isotope 151Tb. The latter would then form a so-called "matched pair" with 149Tb, but also with the beta(-)-emitter 161Tb. In this paper, we present the opportunities for innovative medical radioisotopes at ISOL@MYRRHA
AB - The wide spectrum of radioactive ion beams that can be produced and the fact that they can be obtained essentially carrier free, makes ISOL facilities a unique tool for preclinical studies of innovative radioisotopes. Such kind of studies is being carried out already at existing facilities, like at CERN-ISOLDE. An illustrative example is the production of 149Tb, for which promising results were observed in a dedicated alpha-therapy study on Severe Combined Immuno-Deficient (SCID) mice. However, the demand for beam time at ISOL facilities is extra-ordinary, resulting in typical beam-time periods for an experiment of several days up to two weeks at maximum. ISOL@MYRRHA, on the other hand, will be unique in the sense that programs in need of extended beam times will be prioritized. In combination with the intense RIBs, this might open the possibility to produce in a systematic manner innovative carrier-free radioisotopes like, for example, the alpha-emitter 149Tb and the PET isotope 151Tb. The latter would then form a so-called "matched pair" with 149Tb, but also with the beta(-)-emitter 161Tb. In this paper, we present the opportunities for innovative medical radioisotopes at ISOL@MYRRHA
KW - medical radioisotopes
KW - ISOL@MYRRHA
KW - radioactive ion beams 149Tb
UR - http://ecm.sckcen.be/OTCS/llisapi.dll/open/ezp_135208
UR - http://ecm.sckcen.be/OTCS/llisapi.dll/open/ezp_135208_2
UR - http://knowledgecentre.sckcen.be/so2/bibref/11467
U2 - 10.1016/S0167-8140(12)70189-5
DO - 10.1016/S0167-8140(12)70189-5
M3 - Article
VL - 102
SP - 111
EP - 111
JO - Radiotherapy & Oncology Journal
JF - Radiotherapy & Oncology Journal
IS - 1
T2 - ICTR-PHE 2012 Conference
Y2 - 27 February 2012 through 2 March 2012
ER -